Nugenics Research Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.12 M
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 6542.55%
- Profit Growth 84.33%
- Ebitda 75.64%
- Net Worth -24.48%
- Total Assets -23.70%
About Nugenics Research
Nugenics Research Private Limited (NRPL) is a Private Limited Indian Non-Government Company incorporated in India on 25 April 2018 (Six years and nine months 10 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.12 M, as per Ministry of Corporate Affairs (MCA) records.
Jay Arora and Harshvardhan Sanghavi serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999MH2018PTC308550
-
Company No.
308550
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
25 Apr 2018
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Nugenics Research?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jay Arora
|
Director | 02-Mar-2020 | Current |
|
Harshvardhan Sanghavi
|
Director | 25-Apr-2018 | Current |
Financial Performance of Nugenics Research.
Nugenics Research Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 6542.55% increase. The company also saw a substantial improvement in profitability, with a 84.33% increase in profit. The company's net worth observed a substantial decline by a decrease of 24.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nugenics Research?
In 2021, Nugenics Research had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Birchwood Capital LlpJay Arora is a mutual person
-
Birchwood Holdings Llp
Jay Arora is a mutual person
-
Imperial Multi Ventures Private Limited
Jay Arora is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nugenics Research?
Unlock and access historical data on people associated with Nugenics Research, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nugenics Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nugenics Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
